AU-07 is under clinical development by Aucentra Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AU-07’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AU-07 is under development for the treatment of hematological malignancies, high-risk MDS, triple-negative breast cancer, colon cancer, lung cancer, prostate cancer, ovarian cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and other MCL1 and MYC-dependent cancers. It is administered through oral route. The drug candidate acts by targeting cyclic dependent kinase (CDK) 9.
Aucentra Therapeutics overview
Aucentra Therapeutics is an Australian developer of targeted cancer therapeutics. It carries out pre-clinical drug development, drug discovery and research and development activities.
For a complete picture of AU-07’s drug-specific PTSR and LoA scores, buy the report here.